JPRN-jRCTs011180020已完成未知
Hypoxia imaging with 18F-Misonidazole PET in brain metastasis - FMISO-BM
Takashi Mori0 个研究点目标入组 25 人开始时间: 2019年3月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
The FMISO accumulation positivity rate of metastatic brain tumors was 39.8%, and the risk ratio of tumor regrowth in the accumulation positive group to the FMISO accumulation negative group was 4.60 (95% CI 1.23-17.2), p = 0.0235, indicating a significantly higher risk of regrowth.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)metastatic brain tumor whose maximum diameter is equal to or above 5mm in MRI.
- •2)no treatment history with radiotherapy or surgery to metastatic brain tumor.
- •3)no meningitis carcinomatosa and dissemination in MRI.
- •4)KPS equal to or above 70%.
- •5)Pathologically (histologically or cytologically) proven diagnosis from extra cranial lesion.
- •6)Patients must sign a study-specific informed consent prior to study entry.
排除标准
- •1)patient who can rest in dorsal position for about one hour
- •2)patient with severe claustrophobia
- •4)expectant and nursing mothers
- •5)patient judged unsuitable as a trial subject by the principal investigator
研究者
相似试验
终止
2 期
FMISO-PET in Brain Tumors and SCS EffectMalignant GliomaNCT01868906Bernardino Clavo, MD, PhD6
已完成
不适用
Hypoxia imaging with 18F-Misonidazole PET in brain metastasismetastatic brain tumorJPRN-UMIN000014572Departments of Radiation Oncology, Hokkaido University Hospital25
尚未招募
不适用
hypoxic imaging for brain tumor with 18F-fluoromisonidazole PETbrain tumorJPRN-UMIN000042213Kyoto University Graduate School of Medicine170
已完成
1 期
Clinical Evaluation of the New Hypoxia Imaging Agent HX4Head and Neck CancerLung CancerLiver CancerNCT01213030Siemens Molecular Imaging12
已完成
2 期
HYPONCO - Hypoxia in Brain TumorsAnaplastic GliomaNCT01200134University Hospital, Caen39